Comparative Pharmacology
Head-to-head clinical analysis: ALVIMOPAN versus MOVANTIK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALVIMOPAN versus MOVANTIK.
ALVIMOPAN vs MOVANTIK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alvimopan is a peripherally acting mu-opioid receptor antagonist (PAMORA). It selectively blocks mu-opioid receptors in the gastrointestinal tract without crossing the blood-brain barrier, thereby reversing opioid-induced constipation without affecting central analgesia.
Selective antagonist of peripheral mu-opioid receptors; inhibits opioid binding without affecting central analgesic effects.
12 mg orally twice daily, administered with or without food, starting at least 30 minutes before the first dose of opioid analgesic, then twice daily at approximately 12-hour intervals for up to 15 days; or 12 mg once daily for patients receiving a once-daily opioid regimen.
12.5 mg orally once daily; may increase to 25 mg once daily if tolerated, not to exceed 25 mg daily.
None Documented
None Documented
Clinical Note
moderateAlvimopan + Naloxegol
"The risk or severity of adverse effects can be increased when Alvimopan is combined with Naloxegol."
Clinical Note
moderateAlvimopan + Methylnaltrexone
"The risk or severity of adverse effects can be increased when Alvimopan is combined with Methylnaltrexone."
Clinical Note
moderateMethadone + Alvimopan
"The risk or severity of adverse effects can be increased when Methadone is combined with Alvimopan."
Clinical Note
moderateBuprenorphine + Alvimopan
Terminal elimination half-life is approximately 10-17 hours in patients with normal renal function; prolonged in severe renal impairment.
Terminal elimination half-life is approximately 7–11 hours in healthy subjects; prolonged in severe renal impairment (up to ~15 hours).
Primarily fecal (approximately 96%) as unchanged drug; renal excretion accounts for <1%.
Primarily fecal (up to 76% of absorbed dose) and renal (up to 23% of absorbed dose as unchanged drug and metabolites).
Category C
Category C
Peripherally Acting Mu-Opioid Receptor Antagonist
Peripherally Acting Mu-Opioid Receptor Antagonist
"The risk or severity of adverse effects can be increased when Buprenorphine is combined with Alvimopan."